Kyverna Therapeutics, Inc. (KYTX)
8.23
-0.19
(-2.26%)
USD |
NASDAQ |
Aug 24, 16:00
8.23
0.00 (0.00%)
After-Hours: 20:00
Kyverna Therapeutics Net Income (Quarterly) : -38.32M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.32M |
| March 31, 2026 | -39.73M |
| December 31, 2025 | -37.80M |
| September 30, 2025 | -36.79M |
| June 30, 2025 | -42.08M |
| March 31, 2025 | -44.64M |
| December 31, 2024 | -37.49M |
| September 30, 2024 | -34.49M |
| Date | Value |
|---|---|
| June 30, 2024 | -28.80M |
| March 31, 2024 | -26.69M |
| December 31, 2023 | -20.67M |
| September 30, 2023 | -15.46M |
| June 30, 2023 | -13.09M |
| March 31, 2023 | -11.14M |
| December 31, 2022 | -8.496M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cartesian Therapeutics, Inc. | 13.72M |
| Allogene Therapeutics, Inc. | -42.68M |
| Beam Therapeutics, Inc. | -122.68M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 38.32M |
| EPS Diluted (Quarterly) | -0.6292 |
| Enterprise Value | 351.99M |
| Earnings Yield | -35.67% |
| Normalized Earnings Yield | -35.67 |